Table 2.
Association of mannose-binding lectin concentration with acute COPD exacerbations
| Variable |
MBL concentration (ng/mL)
|
|||||
|---|---|---|---|---|---|---|
| ≤100 | >100 | ≤500 | >500 | >50 and ≤1000** | >1000 | |
| Days to first AECOPD, median (95% CI) | ||||||
| All patients | 326 (215–370) | 223 (193–242) | 236 (193–279) | 223 (188–242) | 231 (194–266) | 211 (175–242) |
| Azithromycin | NA* | 277 (227–320) | 289 (214, ≥375) | 266 (223–320) | 302 (245–376) | 234 (197–299) |
| Placebo | 326 (215–370) | 173 (139–215) | 213 (133–246) | 166 (136–216) | 178 (131–224) | 171 (136–232) |
| Rate of AECOPD per patient-year (95% CI) | ||||||
| All patients | 1.03 (0.47–1.59) | 1.65 (1.50–1.80) | 1.70 (1.29–2.11) | 1.62 (1.48–1.76) | 1.67 (1.44–1.90) | 1.61 (1.44–1.79) |
| Azithromycin | 1.04 (0.00–2.25) | 1.46 (1.29–1.63) | 1.29 (0.96–1.62) | 1.50 (1.30–1.70) | 1.43 (1.18–1.68) | 1.49 (1.25–1.72) |
| Placebo | 1.03 (0.34–1.71) | 1.84 (1.61–2.08) | 2.01 (1.34–2.67) | 1.75 (1.56–1.95) | 1.89 (1.52–2.26) | 1.76 (1.51–2.02) |
Notes:
*
Too few patients for life table analysis;
**
number of subjects in this column is one greater than the number indicated on Figure 3 because the life table analyses were truncated at 365 days eliminating one patient.
Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; CI, confidence interval; MBL, mannose-binding lectin.